In schizophrenia, dopaminergic hyperfunction in the limbic system and dopaminergic hypofunction in the frontal cortex are discussed to be the main neurotransmitter disturbances. Recent research provides further insight that glutamatergic hypofunction might be the cause for this dopaminergic dysfunction. In major depression, in contrast, glutamatergic hyperfunction seems to be closely related to the lack of serotonergic and noradrenergic neurotransmission and to the core symptoms of major depression. Therefore, glutamatergic dysfunction seems to be a common pathway in the neurobiology of schizophrenia and depression. The function of the glutamatergic system is closely related to the immune system and to the tryptophankynurenine metabolism, which both seem to play a key role in the pathophysiology of schizophrenia and major depression (Müller and Schwarz, 2006, 2007).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Müller, N., Schwarz, M.J. (2008). Molecular Pathogenesis for Schizophrenia and Major Depression. In: Gendelman, H.E., Ikezu, T. (eds) Neuroimmune Pharmacology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-72573-4_36
Download citation
DOI: https://doi.org/10.1007/978-0-387-72573-4_36
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-72572-7
Online ISBN: 978-0-387-72573-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)